Evidence map›Paper›PMID 40019400›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma.

Wenchao Zhang, Chi Yin, Lin Qi, Zhongyue Liu, Ruiling Xu, Chao Tu, Zhihong Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenchao ZhangDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Chi YinDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Lin QiDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhongyue LiuHunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, 410011, China.
Ruiling XuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Chao TuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhihong LiDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.ORCID https://orcid.org/0000-0002-1944-9671

Funding

Changsha Municipal Natural Science Foundation kq2403077First Young Elite Scientists Sponsorship Program by CAST (Doctoral Student Special Program) and Hunan Province Science and Technology Talent Support Project 2024TJ-X66Hunan Provincial Administration of Traditional Chinese Medicine Project D2022117Hunan Provincial Health High-Level Talent Scientific Research Project R2023054Hunan Provincial Natural Science Foundation of China 2022JJ30843Hunan Provincial Natural Science Foundation of China 2024JJ6559Hunan Provincial Natural Science Foundation of China 2024JJ6572National Key Research and Development Program of China 2023YFC2507603National Natural Foundation of China 82172500National Natural Foundation of China 82272664Science and Technology Innovation Program of Hunan Province 2023RC3085Scientific Research Program of Hunan Provincial Health Commission B202304077077Scientific Research Program of Hunan Provincial Health Commission W20243104State-funded Postdoctoral Researchers Plan of China GZC20233188
6 · The paper itself

Abstract

Chemoresistance represents a major challenge for osteosarcoma treatment. Despite the improved knowledge of cancer biology, the core determinants of cisplatin (DDP) resistance in osteosarcoma remain unclear and deserve further exploration. Here, RFWD3 is identified as a key regulator of DDP sensitivity in osteosarcoma using a genome-wide CRISPR screen. It is demonstrated that RFWD3 is overexpressed in post-chemotherapy osteosarcoma tissues compared to pre-chemotherapy tissues. Knocking out RFWD3 increased the sensitivity of osteosarcoma cells to DDP treatment. Mechanistically, RFWD3 bound to and ubiquitinated PHGDH at the Lys137 residue, promoting its degradation and conserving cellular oxidized nicotinamide adenine dinucleotide (NAD

Indexed as

Bone NeoplasmsDrug Resistance, NeoplasmNucleotidesOsteosarcomaPhosphoglycerate DehydrogenaseAntineoplastic AgentsCell Line, TumorCisplatinHumansAntineoplastic AgentsCisplatinNucleotidesPhosphoglycerate Dehydrogenasechemoresistancecisplatinnucleotide metabolismosteosarcomaRFWD3

Identifiers

PMID40019400
PMCPMC12021087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.